Evidence map›Paper›PMID 39851181›Full record

ArticleNeuro-oncology2025

Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.

Alexander P Landry, Justin Z Wang, Leeor S Yefet, Jeff Liu, Vikas Patil, Wen-Jiang Zhang, Julio Sosa, Yosef Ellenbogen, Chloe Gui, Andrew Ajisebutu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alexander P LandryPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Justin Z WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Leeor S YefetPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jeff LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Vikas PatilPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Wen-Jiang ZhangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Julio SosaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Yosef EllenbogenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Chloe GuiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Andrew AjisebutuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Kenneth AldapeCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-5119-7550
Andrew GaoDivision of Laboratory Medicine and Pathobiology, University Health Network, Toronto, ON, Canada.
Thomas KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.
Eric X ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-4581-8848
Farshad NassiriPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gelareh ZadehPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6637-4502

Funding

Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumorsR01CA263196 · NCI · UNIVERSITY HEALTH NETWORK · PI Daniel De Carvalho, Gelareh Zadeh · 2022 to 2026
$1.9M
CIHRNCI NIH HHS R01 CA263196
6 · The paper itself

Abstract

backgroundOur group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumors), has not been explored.

methodsWe performed untargeted metabolic profiling of meningiomas representing each molecular group and World Health Organization (WHO) grade. Prognostic biochemicals were identified using Cox regression and their biological importance was explored using RNA and protein-based pathway analyses. Validation was performed using targeted high performance liquid chromatography-mass spectrometry (HPLC-MS/MS).

resultsGlobal metabolic profiling identified 560 unique biochemicals. We identified a 21-metabolite outcome signature which is strongly predictive of outcome after adjusting for WHO grade, extent of resection, and receipt of adjuvant radiotherapy (HR = 326.49, 95% CI = 16.72-6375.48, P < .0001). The abundance of N6-trimethyllysine was associated with earlier time to recurrence on our whole cohort (log-rank P = .009) and within hypermetabolic and WHO grade 2 tumors specifically; this was validated using targeted HPLC-MS/MS on two cohorts. Consensus RNA and protein expression analysis demonstrated as association between N6-trimethyllysine abundance and activation of oxidative phosphorylation pathways, which portended worse outcomes in the hypermetabolic subgroup but, interestingly, better outcomes in the proliferative subgroup. By contrast, upregulated pyruvate and lactate transporters were associated with worse outcomes in proliferative meningiomas specifically.

conclusionsThis is the first study to demonstrate a subgroup-specific prognostic role of N6-trimethyllysine in hypermetabolic meningiomas, offering increasingly granular outcome predictions using a widely accessible technique (HPLC-MS/MS). We also suggest fundamental differences in preferred energy utilization between and a potential need for subgroup-specific therapies.

Indexed as

Biomarkers, TumorMeningeal NeoplasmsMeningiomaMetabolomeMetabolomicsAdultAgedChromatography, High Pressure LiquidFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSurvival RateTandem Mass SpectrometryBiomarkers, Tumormeningiomametabolismmolecular classificationoutcome predictionproteomicsRNA sequencing

Identifiers

PMID39851181
PMCPMC12448868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.